Cancer News and Research

Latest Cancer News and Research

Genes in Tasmanian Devil give new hope to children with cancer

Cancer researchers have generated a genetic blueprint of the Tasmanian Devil genome, revealing cancer-associated genes that may answer important questions about adult and childhood cancer.

30 Jun 2011

NLST: CT scans more effective in reducing lung cancer death rates

The National Lung Screening Trial (NLST) is the first scientific study that provides clear evidence that CT screening significantly reduces the death rate due to lung cancer.

30 Jun 2011

Provectus presents additional data on PV-10 at two separate melanoma conferences

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that data and study design features on PV-10 for metastatic melanoma were presented at two separate conferences.

30 Jun 2011

Dendreon receives FDA approval for Los Angeles cancer immunotherapy manufacturing facility

Dendreon Corporation today announced that the U.S. Food and Drug Administration approved its Los Angeles cancer immunotherapy manufacturing facility, allowing the company to continue to increase the availability of PROVENGE across the U.S. to help meet the needs of patients with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.

30 Jun 2011

Pregenen, Cellectis partner to develop meganucleases

Cellectis, the French genome engineering specialist, announced today the signing of a collaboration agreement with Pregenen, an American biotechnology start-up company dedicated to the creation of innovative tools for genome engineering.

30 Jun 2011

Viewpoints: Calif.'s budget, Supreme Court drug rulings, the Avastin debate

The budget is not realistic, counting on fantastical revenue projections as well as a redevelopment gambit that's likely to be blocked in court. It makes deep cuts in state programs that will have unwelcome repercussions in years to come. And if the revenue projections prove to be as overly optimistic as they seem, there will be more damaging cuts to education, child care and health services. Nevertheless, it's a more earnest effort to clean up the state's budget mess than Sacramento has seen in a decade or more.

30 Jun 2011

FDA looks at Avastin risks

The US Food and Drug Administration is holding a two-day hearing that pits the FDA's Center for Drug Evaluation and Research against Genentech, that manufactures breast cancer drug Avastin. A handful of breast cancer patients testified Tuesday that Avastin helped in treating their metastatic breast cancer but a review of studies conducted by the FDA's Center for Drug Evaluation and Research suggests the risks outweigh the benefits of Avastin for treating breast cancer, FDA officials said at the hearing.

29 Jun 2011

Patients, scientists in different corners for cancer drug fight

The drug, Avastin, will be the subject of an unusual Food and Drug Administration hearing to revisit a panel vote last July that steered many doctors away from prescribing the drug for the treatment of breast cancer.

29 Jun 2011

Acetylon to advance ACY-1215 drug candidate with $27M Series B Preferred equity investment round of financing

Acetylon Pharmaceuticals, Inc. announced today that it has completed a $27 million Series B Preferred equity investment round of financing.

29 Jun 2011

LVAD therapy an 'attractive option' for heart failure patients 70 years of age or older

Results of a clinical research study at Sharp Memorial Hospital indicate that patients 70 years of age or older have good functional recovery, survival and quality of life at two years when undergoing left ventricular assist device (LVAD) therapy for heart failure.

29 Jun 2011

A.P. Pharma enters into definitive agreements for $24M private placement of common stock and warrants

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that it has entered into definitive agreements with certain new and existing accredited investors providing for a private placement of common stock and warrants in which the Company will receive $24 million in gross proceeds.

29 Jun 2011

GenSpera and University of Copenhagen collaborate on 'Sustainable Production of Thapsigargin using Light'

GenSpera, Inc. has entered into a cooperation agreement with the University of Copenhagen, in Copenhagen, Denmark, to collaborate on the "SPOTLight" (Sustainable Production of Thapsigargin using Light) project.

29 Jun 2011

PEP intervention increases breast cancer awareness

Educating women about breast cancer increases their knowledge about the disease should they develop a symptom - and could help increase survival from breast cancer, new research today shows.

29 Jun 2011

Threshold commences combination Phase 1/2 trial of TH-302 and sunitinib for RCC, GIST and PNET

Threshold Pharmaceuticals, Inc., today announced the initiation of a Phase 1/2 dose escalation clinical trial of TH-302 in combination with sunitinib in patients with advanced renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) and pancreatic neuroendocrine tumor (PNET).

29 Jun 2011

DiagnoCure, Signal Genetics enter commercialization collaboration for Previstage GCC Colorectal Cancer Staging Test

Signal Genetics, a privately held predictive genetic testing company focusing on oncology, and DiagnoCure, Inc., a life sciences company that develops and commercializes high-value cancer diagnostic tests, today announced a collaboration arrangement valued at US$13.3M over the first five years.

29 Jun 2011

New prostate cancer drugs bring cost of care into spotlight

Meanwhile, results from a three-decade Swedish study found that women who have mammograms have a lower death rate from breast cancer — a finding that some say may ease recent controversies around the screening procedure.

29 Jun 2011

Amorfix fiscal 2011 net loss decreases to $3,330,437

Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced its operational and financial results for the year ended March 31, 2011, as well as financial results for the fourth quarter.

29 Jun 2011

USPTO awards patent for key therapeutic ingredient in CNVN202 targeted molecular cancer therapy

Convergen LifeSciences, Inc. announced today that a United States Patent has been awarded by the U.S. Patent and Trademark Office jointly to The University of Texas System Board of Regents and The Secretary, U.S. Department of Health and Human Services.

29 Jun 2011

Some adult survivors of childhood cancer are at risk for multiple cancers

The largest study yet of adult childhood cancer survivors found that the first cancer is just the beginning of a lifelong battle against different forms of the disease for about 10 percent of these survivors.

29 Jun 2011

Diet sodas and artificial sweeteners may not be healthy alternatives

In the constant battle to lose inches or at least stay the same, we reach for the diet soda. Two studies presented June 25 and 27 at the American Diabetes Association's Scientific Sessions in San Diego suggest this might be self-defeating behavior.

29 Jun 2011

Cancer News and Research

Latest Cancer News and Research

Genes in Tasmanian Devil give new hope to children with cancer

NLST: CT scans more effective in reducing lung cancer death rates

Provectus presents additional data on PV-10 at two separate melanoma conferences

Dendreon receives FDA approval for Los Angeles cancer immunotherapy manufacturing facility

Pregenen, Cellectis partner to develop meganucleases

Viewpoints: Calif.'s budget, Supreme Court drug rulings, the Avastin debate

FDA looks at Avastin risks

Patients, scientists in different corners for cancer drug fight

Acetylon to advance ACY-1215 drug candidate with $27M Series B Preferred equity investment round of financing

LVAD therapy an 'attractive option' for heart failure patients 70 years of age or older

A.P. Pharma enters into definitive agreements for $24M private placement of common stock and warrants

GenSpera and University of Copenhagen collaborate on 'Sustainable Production of Thapsigargin using Light'

PEP intervention increases breast cancer awareness

Threshold commences combination Phase 1/2 trial of TH-302 and sunitinib for RCC, GIST and PNET

DiagnoCure, Signal Genetics enter commercialization collaboration for Previstage GCC Colorectal Cancer Staging Test

New prostate cancer drugs bring cost of care into spotlight

Amorfix fiscal 2011 net loss decreases to $3,330,437

USPTO awards patent for key therapeutic ingredient in CNVN202 targeted molecular cancer therapy

Some adult survivors of childhood cancer are at risk for multiple cancers

Diet sodas and artificial sweeteners may not be healthy alternatives

Industry Focus eBook - Oncology (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in